KP
AVDL

Keel Point’s Avadel Pharmaceuticals AVDL Stock Holding History

Keel Point’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,569
Closed -$100K – 262
2022
Q1 		$100K Hold
14,569
– – 0.02% 259
2021
Q4 		$118K Sell
14,569
-41,500
-74% -$379K 0.01% 264
2021
Q3 		$549K Sell
56,069
-51,551
-48% -$406K 0.07% 144
2021
Q2 		$724K Buy
107,620
+64,569
+150% +$513K 0.08% 135
2021
Q1 		$389K Sell
43,051
-49,173
-53% -$398K 0.04% 175
2020
Q4 		$616K Hold
92,224
– – 0.05% 139
2020
Q3 		$465K Buy
92,224
+20,000
+28% +$146K 0.04% 141
2020
Q2 		$584K Buy
72,224
+1,551
+2% +$13.7K 0.06% 113
2020
Q1 		$561K Buy
70,673
+30,673
+77% +$236K 0.07% 107
2019
Q4 		$302K Buy
+40,000
New +$211K 0.03% 156

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $282M AUM 62.81% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Keel Point's AVDL Position: Q2 2022 in Review

Keel Point sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 14,569 shares — an estimated $100K sold.

Keel Point first reported a position in AVDL in Q4 2019 and held it in 10 quarters. The position peaked at $724K in Q2 2021. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

  • Keel Point reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Keel Point sold 14,569 Avadel Pharmaceuticals shares in Q2 2022, an estimated $100K.
  • Keel Point first reported a position in Avadel Pharmaceuticals in Q4 2019 and held it in 10 quarters.
  • Keel Point's Avadel Pharmaceuticals position peaked at $724K in Q2 2021.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Keel Point's 13F filing for Q2 2022, filed 11 Aug 2022.